In 2000, Rhodes et al.10 demonstrated that there was considerable variability between laboratories (200 laboratories in 26 countries) regarding ER results, especially in relation to detection of breast cancers with low ER positivity, with a false-negative rate ranging from 30% to 60%. This evidence concerns the gene ESR1 and breast carcinoma.